Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
- 224 Downloads
Uric acid (UA), the final product of purine catabolism, may be associated with an increased risk of cardiovascular disease.
The aim of this meta-analysis of randomized placebo-controlled trials was to evaluate whether lowering serum UA (SUA) levels with allopurinol is associated with improved flow-mediated dilation (FMD), a validated marker of early vascular damage.
A literature search was carried out from inception until 20 June 2017. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate.
Meta-analysis of data from the ten eligible randomized controlled trials (RCTs), with 670 subjects, suggested a significant increase in FMD following allopurinol treatment (weighted mean difference [WMD] 1.79%, 95% confidence interval [CI] 1.01–2.56, p < 0.001; I 2: 86.77%). The effect size was robust and remained significant after omission of each single study. Subgroup analyses of RCTs based on the administered dose or duration of treatment did not reveal any significant impact of these variables on FMD change. Nor was a significant association found between allopurinol-induced changes in SUA levels and FMD (slope 0.46, p = 0.253), whereas baseline FMD significantly influenced the degree of FMD improvement following allopurinol treatment (slope 0.52, p = 0.022). Nitroglycerin-mediated dilation was not altered by allopurinol treatment (WMD 0.88%, 95% CI − 1.15–2.91, p = 0.395; I 2: 80.88%).
This meta-analysis of available RCTs suggests a significant benefit from allopurinol intake in increasing FMD in humans, independent of its effect on SUA levels.
AFGC, MP, MB and AS conceived and designed the work and contributed to the drafting of the manuscript. Arrigo F.G. Cicero and Matteo Pirro performed the searches and extracted data. Amirhossein Sahebkar performed the statistical analysis. GFWa, DPM and MB contributed to the interpretation of the work and revised the manuscript critically for important intellectual content. All authors approved the final manuscript and agree to be held accountable for all aspects of the work.
Compliance with Ethical Standards
Conflicts of interest
Prof. Watts has received honoraria for advisory boards and lectures from Amgen, Sanofi, Regeneron, Kowa and MSD. Prof. Banach has served on the speaker’s bureau and as an advisory board member for Amgen, Sanofi, Aventis and Lilly. Prof. Mikhailidis has given talks and attended conferences sponsored by MSD, Libytec and AstraZeneca. No professional writer was involved in the preparation of this meta-analysis.
This meta-analysis was written independently; no company or institution supported it financially.
- 14.Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507–32.PubMedCrossRefGoogle Scholar
- 17.Higgins JPT, Green S. Handbook for systematic reviews of interventions. Version 5.0.2 ed. London: The Cochrane Collaboration; 2009Google Scholar
- 19.Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester: Wiley; 2000.Google Scholar
- 23.Yiginer O, Ozcelik F, Inanc T, Aparci M, Ozmen N, Cingozbay BY, Kardesoglu E, Suleymanoglu S, Sener G, Cebeci BS. Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. Clin Res Cardiol. 2008;97(5):334–40.PubMedCrossRefGoogle Scholar
- 26.Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan A, Kalay N. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182–7.PubMedCrossRefGoogle Scholar
- 30.Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, Papageorgiou N, Papadimitriou CA, Dimopoulos MA, Stefanadis C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7.PubMedCrossRefGoogle Scholar
- 37.Cicero AF, Rosticci M, Bove M, Fogacci F, Giovannini M, Urso R, D’Addato S. Borghi C; Brisighella Heart Study Group. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. Ann Med. 2017;49(4):275–82.PubMedCrossRefGoogle Scholar
- 50.Masoura C, Pitsavos C, Aznaouridis K, Skoumas I, Vlachopoulos C, Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis. 2011;214(1):129–38.PubMedCrossRefGoogle Scholar